SCM
CAMP icon

Stonepine Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Stonepine Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07M Hold
1,389,622
– – 3.43% 7
2026
Q1 		$6.13M Buy
1,389,622
+1,160,728
+507% +$5.51M 2.45% 8
2025
Q4 		$1.4M Buy
+228,894
New +$974K 1.02% 29

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stonepine Capital Management's CAMP Position: Q2 2026 in Review

Stonepine Capital Management held its CAMP4 Therapeutics (CAMP) position steady in Q2 2026 at 1,389,622 shares worth $6.07M. The position accounts for 3.43% of the portfolio, ranked #7.

Stonepine Capital Management first reported a position in CAMP in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.13M in Q1 2026. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Stonepine Capital Management held 1,389,622 shares of CAMP4 Therapeutics worth $6.07M as of Q2 2026.
  • Stonepine Capital Management left its CAMP4 Therapeutics share count unchanged in Q2 2026.
  • CAMP4 Therapeutics made up 3.43% of Stonepine Capital Management's portfolio in Q2 2026, its #7 holding.
  • Stonepine Capital Management first reported a position in CAMP4 Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Stonepine Capital Management's CAMP4 Therapeutics position peaked at $6.13M in Q1 2026.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.